ロード中...
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an impo...
保存先:
| 出版年: | Nat Commun |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279809/ https://ncbi.nlm.nih.gov/pubmed/30514931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07644-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|